Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3823 plus bevacizumab maintenance in advanced ovarian, fallopian tube and primary peritoneal cancer
CTR20231645Phase 3Terminated
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TQB3823 in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jun 2023; status: terminated.
02
Drugs
TQB3823
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20231645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231645.